Skip to main content
. 2018 Apr 26;126(4):047014. doi: 10.1289/EHP2698

Figure 1.

Figure 1A is a bar graph plotting relative expression of CYP19 transcripts in Hs578t cells (y-axis) across DMSO, Dex 100 nanomolar, Frsk 10 micromolar, and VEGF 2.5 nanograms per milliliter (x-axis) for the coding region and promoters I.4, P II, I.3, and I.7 transcripts. Figure 1B is a bar graph plotting aromatase activity in Hs578t cells (percentage of DMSO) (y-axis) across DMSO, Dex 100 nanomolar, Frsk 10 micromolar, VEGF 2.5 nanograms per milliliter, and Form 1 micromolar (x-axis).

(A) Relative expression of CYP19 coding region (nonpromoter-specific or total), and I.4, PII, I.3, and I.7 promoter-derived CYP19 transcripts in Hs578t cells (fold DMSO control). (B) Aromatase catalytic activity in Hs578t cells exposed to dexamethasone (DEX) 100 nM, forskolin (Frsk) 10μM, vascular endothelial growth factor (VEGF) 2.5 ng/mL, or formestane (Form) 1μM. Experiments were performed in triplicate with three different cell passages; per experiment, each treatment was tested in triplicate. Cells were exposed to treatments for 24 h. *, p<0.05. Statistically significant difference between treatments compared with DMSO (Student t-test).